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Abstract Poly (ADP-ribose) polymerase-1 (PARP-1)
is a DNA-binding enzyme involved in DNA damage
processing, apoptosis, and genetic stability. Many
lines of evidence suggest that PARP-1 is implicated in
transcriptional regulation of various genes through the
modulation of chromatin structure or through direct
interaction with transcription factors and/or transcription
factor-binding sites. In the present study, we applied
TaqMan Low-Density Array analyses to investigate the
expression of genes involved in apoptotic cell death
induced by an alkylating agent. Using RNA interfer-
ence, we determined the roles of PARP-1 and PARP-2 in
transcriptional regulation during apoptosis in HeLa
cells. Of the 93 genes monitored, 33 differentially
expressed genes were identified after induction of
apoptosis. Whereas the down-regulation of PARP-1
and PARP-2 had no impact on gene expression per se,
we observed that Bcl10, c-Rel, and tumor necrosis
factor-related apoptosis-inducing ligand receptor-1 and -
2 are differentially expressed after induction of apopto-
sis in a PARP-1-dependent manner. These findings
suggest that PARP-1—but not PARP-2—is required for
proper expression of major genes involved in regulation
of apoptosis.
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Abbreviations
ACTB beta-actin
Bcl10 B-cell lymphoma 10
DMEM Dulbecco’s modified Eagle’s
medium
FBS fetal bovine serum
GAPDH glyceraldehyde-3-phosphate
dehydrogenase
MNNG N-methyl-N′-nitro-N′-
nitrosoguanidine
PAR poly(ADP-ribose)
PARP-1 PAR polymerase 1
PARP-2 PAR polymerase 2
RNAi RNA interference
siRNA small interfering RNA
TLDA TaqMan® Low-Density Array
TRAIL-R1 and -R2 TNF-related apoptosis-
inducing ligand receptor-1
and -2
Introduction
In response to DNA damage, poly(ADP-ribose)
polymerase-1 (PARP-1) acts as a DNA nick sensor
and is activated by DNA breaks to cleave NAD+ to
nicotinamide and adenosine diphosphate (ADP)-ribose.
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Thereby, long branched poly(ADP-ribose) polymers
(PAR) are synthesized and covalently attached to
nuclear acceptor proteins, including PARP-1 itself
(Schreiber et al. 2006). Several lines of evidence
support a role of PARP-1 and PAR in the regulation
of gene expression, and at least two mechanisms of
transcriptional regulation have been described: (1)
PARP-1 can directly modify structural proteins that
constitute chromatin, and (2) PARP-1 functions as an
enhancer/promoter-binding cofactor that can act in
conjunction with other transcription-related factors
(D’Amours et al. 1999; Hassa and Hottiger 2002;
Haince et al. 2006). PARP-1 exerts its effects in
modulating chromatin by directly (ADP-ribosyl)ating
core histones and chromatin-associated proteins, there-
by promoting the dissociation of nucleosomes and the
decondensation of higher-order chromatin (D’Amours
et al. 1999). The polyanionic PAR can act as a local
matrix for core histones released from destabilized
nucleosomes, providing further access to DNA
(Althaus 1992; Realini and Althaus 1992). One
example of histone-modifying PARP-1 activity is puff
formation in Drosophila polytene chromosomes, which
presents PARP-1-dependent accumulation of PAR at
decondensed, transcriptionally active loci (Tulin and
Spradling 2003). Activation of transcription was also
shown to be induced by a histone H1 high-mobility
group B exchange event triggered by PARP-1 activa-
tion, whereas on the other hand, the nucleosome-
binding properties of PARP-1 were shown to promote
the formation of transcriptionally repressed chromatin
structures (Kim et al. 2004; Ju et al. 2006). Further-
more, recently Krishnakumar observed a reciprocal
pattern of binding of histone H1 and PARP-1 at many
RNA polymerase II-transcribed promoters that speci-
fies transcriptional outcomes (Krishnakumar et al.
2008). With respect to the second mechanism of
regulatory activity, the role of PARP-1 in transcription
by directly altering the activity of enhancers and
promoters is well-established. The PARP-1 regulatory
effect at enhancers and promoters occurs in large part
by functional interaction between PARP-1 and various
non-histone proteins. Thereby, PARP-1 enzymatic
activity is necessarily required for its transcription-
regulating functions in some cases, whereas it is not
needed in others (Kraus and Lis 2003). Several studies
revealed that PARP-1 promotes activator-dependent
transcription by interacting with RNA polymerase
II-associated factors (Butler and Ordahl 1999), tran-
scription enhancer factor 1 (TEF1), and a large number
of transcription factors including AP-2, b-Myb, YY-1,
Oct-1, NF-κB, and p53 (Oei et al. 1997; Nie et al. 1998;
Kannan et al. 1999; Oliver et al. 1999; Cervellera and
Sala 2000; Hassa et al. 2003; Wesierska-Gadek et al.
2003). As a co-repressor, PARP-1 modulates the
expression of RXR-regulated genes (Miyamoto
et al. 1999) and of a mu opioid receptor gene (Choi
et al. 2008), as well as of the PARP-1 gene itself
(Soldatenkov et al. 2002). In addition, Ju et al. (2004)
identified PARP-1 as a component of a regulatory
circuit, in which it plays a dual role as a component of
a repressive complex that is also essential for gene
activation.
Although less well described, other PARP family
members also contribute to transcriptional regulation
(Schreiber et al. 2006). Among the members of the
PARP gene family characterized so far, PARP-2
shows the highest homology with the catalytic domain
of PARP-1 and contributes, although to a lesser extent,
to the formation of ADP-ribose polymers in response
to DNA damage (Ame et al. 1999; Hassa et al. 2006).
PARP-2 interacts with thyroid transcription factor-1
(TTF1) and regulates the expression of surfactant
protein-B in lungs (Maeda et al. 2006).
In the present study, we used RNA interference
(RNAi) in human cells to selectively down-regulate
PARP-1 and PARP-2 in order to determine their
individual contribution to apoptotic cell death at the
transcriptional level. We chose a low-dose (50 μM)
N-methyl-N′-nitro-N′-nitrosoguanidine (MNNG) treat-
ment that triggers apoptotic cell death in HeLa cells as
previously described (Cohausz et al. 2008). This type
of cell death involves moderate activation of PAR
synthesis, moderate changes in the ADP/ATP ratio of
cells, activation of caspases-7 and -9, proteolytic
processing of PARP-1, and apoptosis-inducing factor
translocation from mitochondria to the nucleus
(Cohausz et al. 2008). Furthermore, we showed that
PARP-1, but not PARP-2, acts as pro-apoptotic factor,
as knockdown of PARP-1—but not PARP-2—led to a
significant increase in cell survival after MNNG
treatment in comparison to control cells (Cohausz
et al. 2008). In the present study, the expression
patterns of 93 marker genes involved in the apoptosis
pathway were investigated using the TaqMan Low-
Density Array (TLDA) technique. Our results suggest
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that, of the two tested PARP enzymes, only PARP-1 is
involved in the regulation of major players of the
apoptosis pathway, namely Bcl10, c-Rel, and tumor
necrosis factor (TNF)-related apoptosis-inducing ligand
receptor-1 and -2 (TRAIL-R1, TRAIL-R2), whereas the
transcription of genes of the apoptosis pathway was not
affected by RNAi-mediated silencing of PARP-2.
Materials and methods
Cell culture
All media and supplements used for cell culturing
were obtained from GIBCO (Invitrogen, Basel,
Switzerland). Human cervical carcinoma cells (HeLa
S3) were cultured at 37°C in a water-saturated 5%
CO2/95% air atmosphere, in Dulbecco’s modified
Eagle’s medium (DMEM) containing 4,500 mg/l
glucose and supplemented with 10% (v/v) fetal bovine
serum and antibiotics (complete DMEM).
Synthesis of siRNAs (small interfering RNAs)
and transfection
Small interfering RNAs (siRNAs) were synthesized in
vitro from oligonucleotide templates (Microsynth,
Balgach, Switzerland) using a siRNA construction
kit (Ambion), according to manufacturer’s instructions.
Purified siRNAs were dissolved in water at a concen-
tration of 20 μMand stored at −80°C until use. As target
for RNAi, 21 nucleotide sequences in the human coding
region of PARP-1 (siRNA-P1-I, 5′-AAGAGCGAT
GCCTATTACTGC-3′) and PARP-2 (siRNA-P2, 5′-
AAGATGATGCCAGAGGAACTC-3′) cDNA were
chosen as previously described (Cohausz et al. 2008).
A scrambled version of siRNA was also synthesized
and used as a negative control. For PARP-1 down-
regulation assays, an additional siRNA specific for
human PARP-1 (siRNA-P1-II, 5′-CAUCGAGGUG
GCCUACAGU-3′) was designed and obtained from
Microsynth. Cells were grown to 50–70% confluence
in six-well plates and transfected with siRNAs at a
final concentration of 80 nM in 1,000 μl OptiMEM,
using siPORT Amine (Ambion) as the transfection
reagent. After incubation for 4 h at 37°C, medium was
changed to 3 ml per well complete DMEM, and cells
were allowed to grow for 30 h.
MNNG treatment
Thirty hours after transfection with siRNA, cells were
harvested by trypsinization, resuspended in complete
DMEM and seeded into six-well plates. MNNG was
dissolved in dimethyl sulfoxide at 2.0 M and diluted
in complete DMEM to a final dilution of 50 μM just
before use. After attachment of cells to the bottom of
the plates, complete DMEM containing MNNG was
added to exponentially growing cells in six-well
plates, and cells were incubated at 37°C for 6 h.
RNA extraction and reverse transcription
Total RNA was isolated from untreated HeLa cells
and from HeLa cells treated with 50 μM MNNG for
6 h. Cells were washed with phosphate-buffered saline
(PBS) and lysed directly in the lysis buffer from
RNeasy® Mini Kit (QIAGEN, Hilden, Germany).
Lysates were homogenized using a QIAshredder® spin
column (QIAGEN), and total RNA was isolated with
ion exchange spin columns (QIAGEN RNeasy® Mini
Kit; QIAGEN). Total RNA (1.5 μg) was converted to
single-stranded cDNA using the High-Capacity cDNA
Reverse Transcription Kit with RNase Inhibitors
according to the manufacturer (Applied Biosystems,
Foster City, CA, USA).
mRNA gene analyses by quantitative reverse
transcriptase polymerase chain reaction
PredesignedTaqManLow-Density Arrays (96 TaqMan®
Gene Expression assay preconfigured in a 384-well
format, Part no. 437816, microfluidic cards; Applied
Biosystems), were used in a two-step reverse transcrip-
tase polymerase chain reaction (RT-PCR) process using
the ABI Prism 7900HT Sequence Detection System
(Applied Biosystems) with a TaqMan Low-Density
Array Upgrade (Applied Biosystems). Each cDNA
sample (100 μl) was added to an equal volume of 2×
TaqMan Universal PCR Master Mix (Applied Biosys-
tems). After gentle mixing, the solution was transferred
into a loading port on a TLDA card (Applied Bio-
system). Each of the samples were analyzed in a single
TLDA run with each of the four TLDA experiments
running on separate cards using an Applied Biosystems
7900 HT Fast-Real-Time PCR System. Thermal cycler
conditions were as follows: 2 min at 50°C, 10 min at
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94.5°C and 30 s at 97°C, and 1 min at 59.7°C for
40 cycles. Data acquisition was done according to the
manufacturer’s suggestions. Quantitative real-time PCR
amplification of single genes was performed with
specifically designed primers (Assay-on-demand Gene
Expression products, Applied Biosystems) using an ABI
PRISM7700 cycler, at the default setting program (95°C,
15 s; 60°C, 1 min; 40 cycles). TaqMan gene expression
assays (Applied Biosystems) for Bcl10 (assay ID
Hs00961847_m1), c-Rel (assay ID Hs00968436_m1),
PARP-1 (assay ID Hs00242302_m1), PARP-2 (assay
ID Hs Hs00193931_m1), TRAIL-R1 (assay ID
Hs00269492_m1) and TRAIL-R2 (assay ID
Hs00366272_m1), were used for quantification of
mRNA expression of the respective genes. The expres-
sion of three potential housekeeping genes wasmeasured
in cDNA from siRNA-C and siRNA-P1-I samples in the
absence and presence of MNNG. Glyceraldehydes-
3-phosphate dehydrogenase (GAPDH) showed a good
average expression stability (<0.2) and was selected as
single housekeeping gene using the software geNorm
(Vandesompele et al. 2002). Another internal control
gene, beta-actin (ACTB), was used for validation of
results. For analysis, expression levels of target genes
were normalized to GAPDH and ACTB. Gene expres-
sion values were then calculated based on the ΔΔCt
method, with data normalized to untreated controls
(siRNA-C). Relative quantities (RQ) were determined
using the equation: RQ ¼ 2ΔΔCt. Only genes with
reproducible amplification curves of quadruplicate
determinations were analyzed and presented.
Statistical analyses
Data are expressed as mean±SD. All statistical analyses
were conducted with NCSS (NCSS, Statistical & Power
Analysis Software, Utah, USA). For statistical
analyses, a one-sample t test or a Kruskal–Wallis test
was used as indicated. The analyses were two-tailed,
and p values <0.05 were considered statistically
significant.
Western blot analyses
Cells were washed with ice-cold PBS and then
harvested directly in Laemmli buffer (60 mM Tris–
HCl, pH 6.8, 2% sodium dodecyl sulfate (SDS), 2%
2-mercaptoethanol, 8% glycerol, 0.0025% bromphenol
blue), sonicated and incubated for 1 min at 95°C.
Soluble proteins were collected in the supernatants after
centrifugation, separated by electrophoresis on SDS-
polyacrylamide gels, and finally electroblotted on
polyvinylidene fluoridemembranes (Bio-Rad, Hercules,
CA, USA). Blots were probed with monoclonal anti-
α-tubulin (Sigma, Buchs, Switzerland; 1:5,000), poly-
clonal anti-Bcl10 (Cell Signaling Technology, MA,
USA; 1:1,000), polyclonal anti-cleaved caspase-7 (Cell
Signaling Technology; 1:1,000), polyclonal anti-cleaved
caspase-9 (Cell Signaling Technology; 1:1,000), poly-
clonal anti-c-Rel (Cell Signaling Technology; 1:1,000),
monoclonal anti-GAPDH (Ambion; 1:80,000), mono-
clonal anti-PARP-1 (Alexis, Lausen, Switzerland; c2–
10; 1:5,000), polyclonal anti-PARP-1 p85 fragment
(Promega, Madison, WI, USA; 1:500), monoclonal
anti-PARP-2 (Alexis; 4G8; 1:50), polyclonal anti-
TRAIL-R1 (Millipore, MA, USA; 1:1,000), polyclonal
anti-TRAIL-R2 antibodies (Millipore; 1:500), and
monoclonal anti-α-tubulin antibodies (Sigma; 1:5,000)
in succession. Immunodetection was performed by
enhanced chemiluminescense (PIERCE, Rockford, IL,
USA, ECL detection kit). Images were acquired by
exposure to autoradiographic films and by Luminescent
Image Analyzer (LAS-3000, Fujifilm, Switzerland).
Results
Gene expression profile of MNNG-treated HeLa
cells Based on dose- and time-finding experiments,
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Fig. 1 Western blot analysis of caspase-dependent cleavage of
PARP-1 as well as activated caspase-7 and caspase-9 after
MNNG-induced cell death. Cells were treated with 50 μM for
indicated time points. Immunoblotting of whole cell lysates was
performed with antibodies detecting the full-length form and
the 85-kDa fragment of PARP-1, as well as cleaved caspase-7
and caspase-9
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Table 1 mRNA profile of HeLa cells (siRNA-C and siRNA-P1-I) 6 h after treatment with MNNG
siRNA-C siRNA-P1-l Gene name Gene description
Accession number Fold change
Bcl-2 family-regulated pathway
NM003921.3 −1,0 2,1 BCL10 B-cell CLL/lymphoma 10
NM015367.2 −1,5 −1,3 BCL2L13 BCL2-like 13 (apoptosis facilitator)
NM004050.2 −1,8 −1,7 BCL2L2 BCL2-like 2
NM000633.2 −3,1 −2,5 BCL2 B-cell CLL/lymphoma 2
NM207002.2 1,8 2,7 BCL2L11 BCL2-like 11 (apoptosis facilitator)
NM021127.2 3,0 7,4 PMAIP1 Phorbol-12-myristate-13-acetate-induced protein 1
NM001197.3 7,0 7,1 Bik Bcl2-interacting killer
CARD family
NM006092.1 −1,8 −1,6 CARD4 Caspase recruitment domain-containing protein 4
NM033004.3 −1,9 −1,4 NALP1 NLR family, pyrin domain containing 1
NM181861.1 −3,5 −2,5 APAF1 Apoptotic peptidase activating factor 1
IAP family
NM001166.3 −1,7 −1,1 BIRC2 Baculoviral IAP repeat-containing 2
NM001167.2 −3,2 −2,3 BIRC4 Baculoviral IAP repeat-containing 4
NM182962.1 −3,3 −1,4 BIRC3 Baculoviral IAP repeat-containing 3
NM016252.3 −4,2 −4,4 BIRC6 Baculoviral IAP repeat-containing 6
NM004536.2 9,6 5,9 BIRC1 Baculoviral IAP repeat-containing 1
NF-κB signaling pathway
NM001556.1 −1,6 −1,5 IKBKB Inhibitor of kappa light polypeptide gene enhancer in B-cells, kinase beta
NM014002.2 −1,8 −2,0 IKBKE Inhibitor of kappa light polypeptide gene enhancer in B-cells, kinase epsilon
NM003998.2 −2,2 −1,6 NFKB1 Nuclear factor of kappa light polypeptide gene enhancer in B-cells 1 (p105)
NM013254.2 −2,2 −1,2 TBK1 TANK-binding kinase 1
NM001278.3 −2,3 −1,2 CHUK Conserved helix-loop-helix ubiquitous kinase
NM002908.2 −2,4 1,5 c-Rel v-rel reticuloendotheliosis viral oncogene homolog (avian)
NM021975.2 1,0 1,6 RelA v-rel reticuloendotheliosis viral oncogene homolog A, nuclear factor of
kappa light polypeptide gene enhancerin B-cells 3, p65
NM139239.1 2,1 1,7 TA-NFKBH T-cell activation NFKB-like protein
NM002529.2 2,7 2,3 NFKBIA Nuclear factor of kappa light polypeptide gene enhancer in B-cells
inhibitor, alpha
NM031419.2 2,8 2,2 NFKBIZ Nuclear factor of kappa light polypeptide gene enhancer in B-cells
inhibitor, zeta
TNF receptor pathway
NM003844.2 −1,6 1,2 TRAIL-R1 TNF-related apoptosis inducing ligand receptor 1
NM147187.1 −1,6 1,2 TRAIL-R2 TNF-related apoptosis inducing ligand receptor 2
NM014452.3 −1,6 1,3 TNFRSF21 Tumor necrosis factor receptor superfamily, member 21
NM003804.3 −1,7 1,3 RIPK1 Receptor (TNFRSF)-interacting serine-threonine kinase 1
NM003790.2 −1,8 −2,0 TNFRSF25 Tumor necrosis factor receptor superfamily, member 25
NM003879.3 −1,9 −1,2 CFLAR CASP8 and FADD-like apoptosis regulator
NM000595.2 3,1 4,3 LTA Lymphotoxin alpha (TNF superfamily, member 1)
NM000594.2 3,6 2,2 TNF TNF superfamily, member 2
Others
NM005338.4 −1,9 −2,3 HIP1 Death effector domain containing 2
NM032991.2 −1,0 1,3 Casp3 Caspase 3
NM003768.2 −1,1 2,0 PEA15 Phosphoprotein enriched in astrocytes 15
NM021960.3 1,1 2,3 Mcl1 Myeloid cell leukemia sequence 1 (BCL2-related)
NM133328.2 1,6 1,4 DEDD2 Death effector domain containing 2
Significant transcripts are indicated in italics, p<0.05; siRNA-C: unpaired t test; siRNA-P1: Kruskal–Wallis test.
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50 μM concentrations of MNNG and a treatment
period of 6 h were used in all subsequent experi-
ments. Dose-finding experiments are shown in Figure
S2 of our previous paper (Cohausz et al. 2008) which
is available under http://www.vetpharm.uzh.ch/suppl/
cohausz_et_al_S2.pdf. The time optimum was de-
fined at 6 h after MNNG treatment. At this time point,
we observed a marked increase of the caspase
cleavage fragment of PARP-1, a hallmark of apoptosis,
as well as cleavage of caspase-7 and -9, indicating
apoptotic cell death (Fig. 1).
The transcriptional profiles of a broad set of genes
of the apoptosis pathway were examined by TLDA
containing 93 apoptosis-related genes to assess the
effects of the alkylating agent MNNG on gene
expression. Genes whose expression was significantly
up- or down-regulated in MNNG-treated cells are
listed in Table 1. In HeLa cells, 36% (33 of 93) of
genes showed significant differences in the expression
level (p<0.05, unpaired t test) after MNNG treatment.
Thereby, the expression of 22 genes (24%) was down-
regulated (by a factor of 1.5 to 4.2), and that of 11
genes (12%) was up-regulated (by a factor of 1.6 to
9.6). Of the 33 genes that had altered expression as a
result of treatment with the alkylating agent, those
involved in the Bcl-2 family-regulated pathway, the
NF-κB signaling pathway, and the TNF receptor
pathway as well as genes of the caspase recruitment
domain (CARD) and inhibitor of apoptosis (IAP)
family were found (Table 1). In addition, the
transcriptional profiles of PARP-1 knock-down cells
after MNNG treatment is shown in Table 1. For
comparison of fold change between the two house-
keeping genes, GAPDH and ACTB, scatter plots of
the transcriptional profiles of control as well as
PARP-1 knock-down cells after MNNG treatment
were generated (Fig. 2). The data set obtained after
normalization to GAPDH showed good correlation
with ACTB data with R2 values of 0.90 and 0.98 for
control and PARP-1 knock-down cells, respectively.
Suppression of PARP-1 and PARP-2 by siRNA
technique We knocked down the expression of either
PARP-1 or PARP-2 by use of RNA interference as
previously described (Cohausz et al. 2008). As shown
in Fig. 3a, transfection of HeLa cells with two
different siRNA constructs specific for PARP-1
(siRNA-P1-I and siRNA-P1-II), but not with control
siRNA (siRNA-C), significantly suppressed the ex-
pression of PARP-1 m-RNA. Western blot analyses of
PARP-1 protein expression in the cell homogenates
utilizing an anti-PARP-1 antibody confirmed a sig-
nificant decrease in PARP-1 protein levels at 52
h after transfection (Fig. 3a). Likewise, after knock-
down of PARP-2 by RNAi, the expression of PARP-2
m-RNA and protein level were reduced compared
with that of siRNA-C transfected cells (Fig. 3b).
Analysis of the effects of PARP-1 and PARP-2
deficiency on gene expression To assess the effect of
either PARP-1 or PARP-2 deficiency on gene expres-
sion, we examined the transcriptional profiles of PARP-
1-siRNA- as well as PARP-2-siRNA-transfected HeLa
cells in comparison to control cells by TLDA. Under
basal conditions, PARP-1-, as well as PARP-2-down-
regulated cells, showed no significant changes in the
expression of genes of the apoptosis pathway (data not
shown). By contrast, after MNNG treatment, we
observed significant changes in the expression of major
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Fig. 2 Correlation of fold change after MNNG treatment of
siRNA-C (a) and siRNA-P1-I (b) transfected HeLa cells
determined by normalization to GAPDH and ACTB. y-Axis,
fold change determined by normalization to ACTB; x-axis, fold
change determined by normalization to GAPDH. A trend line
and the corresponding R2 value are presented in each plot
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genes of the apoptosis pathway, namely, Bcl10, c-Rel,
TRAIL-R1, and TRAIL-R2, in PARP-1-silenced cells
in comparison to control cells after normalization to
GAPDH (Fig. 4a) and ACTB (Fig. 4b). The expression
of Bcl10 was 2.0-fold up-regulated in PARP-1-down-
regulated cells after MNNG treatment (siRNA-
P1-I, +MNNG) in comparison to treated control cells
(siRNA-C, +MNNG; Fig. 4a). We also observed
significant differences of Bcl10 expression between
untreated and MNNG-treated PARP-1-down-regulated
cells. Furthermore, the three transcripts c-Rel, TRAIL-
R1, and TRAIL-R2 were significantly up-regulated
3.1-, 2.1- and 2.0-fold in PARP-1-down-regulated cells
after MNNG treatment (siRNA-P1-I, +MNNG) in com-
parison to treated control cells (siRNA-C, +MNNG;
Fig. 4a). Thereby, the initial decrease in the expression
of these genes induced by MNNG treatment of siRNA-
C-transfected cells was abrogated. Moreover, knock-
down of PARP-1 in MNNG-treated cells reversed this
effect and led to an increase in gene expression of the
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Fig. 3 Specific knockdown
of PARP-1 and PARP-2 by
RNA interference. Relative
fold changes of PARP-1
(siRNA-P1-I and siRNA-
P1-II; a) and PARP-2
(siRNA-P2; b) expression
detected by real-time RT-
PCR and Western blot anal-
ysis 2 days after transfection
with siRNA. For real-time
RT-PCR experiments, the
results of at least three in-
dependent experiments with
triplicate determinations are
summarized. Error bars in-
dicate mean±SD in percent
of control (*p<0.05,
unpaired t test)
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transcripts c-Rel, TRAIL-R1, and TRAIL-R2. After
normalization to ACTB, Bcl10, c-Rel, TRAIL-R1, and
TRAIL-R2 were significantly up-regulated 2.0-, 3.1-,
2.1-, and 2.0-fold, respectively, in PARP-1-down-
regulated cells after MNNG treatment (siRNA-
P1-I, +MNNG) in comparison to treated control cells
(siRNA-C, +MNNG; Fig. 4b), which is consistent with
the gene expression patterns observed after normalization
to GAPDH (Fig. 4a).
In order to verify the results from the TLDA
analyses, we compared these data with results
obtained in single-gene real-time RT-PCR experi-
ments for Bcl10, c-Rel, TRAIL-R1, and TRAIL-R2
(Fig. 5). To exclude off-target silencing effects
mediated by specific siRNA, we employed two
different sequences of PARP-1 (siRNA-P1-I and
siRNA-P1-II) in these single-gene real-time RT-PCR
analyses. Data were normalized either to GAPDH
(Fig. 5a) or to ACTB (Fig. 5b). Consistent with the
results of the TLDA analyses, a marked increase in
transcript levels of Bcl10, c-Rel, TRAIL-R1, and
TRAIL-R2 in PARP-1-down-regulated cells was
observed by conventional real-time RT-PCR analyses
of single genes using either of the PARP-1 siRNA
sequences (siRNA-P1-I or siRNA-P1-II; Fig. 5a,b).
In contrast to these findings in PARP-1-silenced
cells, we did not observe any significant changes in
the expression of genes of the apoptosis pathway in
PARP-2-down-regulated cells after MNNG treatment.
Up-regulated expression of specific proteins after
PARP-1 down-regulation in MNNG-treated HeLa
cells The aforementioned changes in the expression
of specific genes observed by TLDA analyses and
single-gene real-time RT-PCR experiments were
verified at protein level by immunoblot analysis.
Antibodies specific for Bcl10, c-Rel, TRAIL-R1,
and TRAIL-R2 revealed an increase in protein
expression for all four proteins in PARP-1-silenced
cells treated with MNNG (siRNA-P1) in comparison
to MNNG-treated control cells (siRNA-C; Fig. 6a).
As shown in Fig. 6b, quantification of Western blot
analyses confirmed increased protein levels that were
1.6-fold for Bcl10, 1.7-fold for c-Rel, 1.5-fold for
TRAIL-R1, and 1.7-fold for TRAIL-R2.
Discussion
Recent reports have demonstrated several coregulator
functions of PARP-1 as activator or co-repressor of
transcription (Kraus and Lis 2003; Hassa et al. 2003;
Ju et al. 2006; Haince et al. 2006). One study attests
to a similar function of PARP-2 (Maeda et al. 2006).
In the present study, we analyzed the contribution of
the two enzymes by combining siRNA-mediated
silencing with TaqMan Low-Density Arrays analyses,
an array method that allows the simultaneous quan-
titative assessment of the gene expression profile of
an entire pathway. Thereby, we focused on the roles
of PARP-1 and PARP-2 in the apoptosis pathway.
Dissecting the contribution of PARP-1 and PARP-2
by RNAi in living cells in the absence of DNA
damage, we observed that neither of the enzymes is
involved in the constitutive expression of apoptosis-
related genes. By contrast, after induction of apoptosis
by low doses of MNNG, our results of the TLDA
analyses revealed four PARP-1-dependent genes,
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whereas none was found to be PARP-2-dependent. We
showed that the four transcripts of Bcl10, c-Rel,
TRAIL-R1, and TRAIL-R2 were up-regulated 2.0-,
3.1-, 2.1-, and 2.0-fold, respectively, in PARP-1-down-
regulated cells (Fig. 5). Furthermore, Bcl10, c-Rel,
TRAIL-R1, and TRAIL-R2 protein levels were also
found to be significantly up-regulated.
Although single genes such as GAPDH have often
been used for normalization purposes in real-time RT-
PCR experiments, expression of ‘housekeeping’
genes can vary (Vandesompele et al. 2002). We chose
GAPDH and ACTB to verify that the results were
independent of the reference gene selected. In
addition, ‘off-target’ effects may be a problem in
RNA interference experiments. Therefore, we present
two sets of results, i.e., each normalized to GAPDH
and to ACTB and each with two different siRNA
sequences for PARP-1.
The transcription factor NF-κB is a homo- or
hetero-dimeric complex made up of members of the
Rel family of DNA binding proteins. In humans, this
family is comprised of c-Rel, Rel B, p50, p52, and
Rel A (p65; Karin and Lin 2002). NF-κB may play an
anti-apoptotic (Beg and Baltimore 1996; Van Antwerp
et al. 1996; Attar et al. 1998; Ravi et al. 2001) and a
pro-apoptotic role (Abbadie et al. 1993; Lipton 1997;
Ryan et al. 2000; Ravi et al. 2001). The c-Rel subunit
of the transcription factor NF-κB has been shown to
induce the expression of TRAIL-R1 and TRAIL-R2,
whereas Rel A inhibits the expression of the receptors
(Ravi et al. 2001; Chen et al. 2003). TRAIL-R1 and
TRAIL-R2 are type I transmembrane proteins containing
cytoplasmic sequences, termed ‘death domains’, recruit-
ing adaptor proteins and activating caspases (Golstein
1997). Tumor-necrosis factor-related apoptosis-in-
ducing ligand triggers apoptosis through engagement
of the death receptors, TRAIL-R1 and TRAIL-R2.
As we observed, concurrent to the up-regulation of
c-Rel, TRAIL-R1, and TRAIL-R2 under apoptotic
conditions in PARP-1-down-regulated cells, it is
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likely that the induction of TRAIL-R1 and TRAIL-
R2 was due to an increased expression of c-Rel.
Intriguingly, TRAIL signaling does not only lead to
the activation of effector caspases and subsequent
initiation of apoptosis but can also induce non-
apoptotic pathways, which includes the activation of
NF-κB, PKB/Akt, and MAPKs (Falschlehner et al.
2007).
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Fig. 6 Protein expression of
specific genes involved in
TRAIL-receptor signalling
and NF-κB pathway after
knockdown of PARP-1 in
MNNG treated HeLa cells.
Cell extracts of siRNA-C-
and siRNA-P1-transfected
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munoblot analysis with anti-
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TRAIL-R2. Quantification of
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by scanning densitometry of
individual bands with
ImageQuant software
(Molecular Dynamics/GE
Healthcare). Error bars indi-
cate mean±SD in percent of
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analyses (*p<0.01, unpaired
t test)
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In addition to genes involved in the TRAIL
signaling pathway, the expression of Bcl10 mRNA
and protein levels were also significantly up-regulated
in PARP-1-down-regulated cells after MNNG treatment.
Bcl10 is a caspase recruitment domain-containing protein
that was originally identified in mucous-associated
lymphoid tissue lymphomas (MALT). Transient over-
expression of wild-type Bcl10 in cell lines both induces
apoptosis and activates NF-κB (Yan et al. 1999; Thome
et al. 1999; Willis et al. 1999; Koseki et al. 1999).
Although Bcl10 was initially shown to act as a pro-
apoptotic factor, there are indications of an anti-
apoptotic role of Bcl10 as well (Hosokawa 2005).
Thereby, Bcl10/MALT-induced NF-κB activation may
contribute to anti-apoptotic action probably through NF-
κB-mediated up-regulation of apoptotic inhibitor genes
(Hosokawa 2005).
Taken together, we observed that only PARP-1, and
not PARP-2, is involved in transcriptional regulation of
genes of the apoptosis pathway. Specific knockdown
of PARP-1 led to an increase in transcription levels of
major genes of the TRAIL pathway as well as of Bcl10,
indicating that PARP-1 acts as a co-repressor of genes
involved in the regulation of apoptosis pathways. Our
previous paper showed that PARP-1, but not PARP-2,
acts as a pro-apoptotic factor, as knockdown of PARP-
1—but not PARP-2—led to a significant increase in
cell survival after MNNG treatment in comparison to
control cells (Cohausz et al. 2008). Due to the
described dual functions (pro- and anti-apoptotic) of
the transcripts Bcl10, TRAIL-R1, and TRAIL-R2, we
suggest that the apoptotic response depends on the
balance of apoptotic signals as mediated by caspases
and anti-apoptotic programmes controlled by NF-κB
favoring a pro-apoptotic role of PARP-1 in cell death
induced by low doses of the alkylating agent MNNG.
The mechanism by which PARP-1 regulates the
expression of Bcl10, c-Rel, TRAIL-R1, and TRAIL-
R2 remains to be elucidated. Recent reports have
shown that PARP-1 can bind sequence specifically to
the promoter region of particular genes and affect the
gene expression (Butler and Ordahl 1999; Akiyama
et al. 2001; Nirodi et al. 2001; Zhang et al. 2002). In
addition, PARP-1 interacts directly with a variety of
transcription factors (Oei et al. 1997; Nie et al. 1998;
Kannan et al. 1999; Oliver et al. 1999; Cervellera and
Sala 2000; Hassa et al. 2003; Wesierska-Gadek et al.
2003) as well as it is involved in the modulation of
chromatin structure (Haince et al. 2006). Another
unanswered question is whether Bcl10 and c-Rel are
direct targets of PARP-1 and whether the enzymatic
activity of PARP-1 is required for their down-
regulation. These aspects, as well as the question
whether the observed phenomenon can be generalized
for DNA damage and other cell types, are now subject
of further studies about transcriptional control mech-
anisms in response to DNA damage.
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